GlaxoSmithKline plc (ADR) (GSK)
$42.26
-0.62 (-1.45%)
| CAPS Rating |
|
|---|---|
| Open | $41.55 |
| Previous Close | $42.88 |
| Daily Range | $41.54 - $42.40 |
| 52-Week Range | $27.15 - $42.70 |
| Market Cap | $119.62B |
| P/E Ratio | 10.89 |
| Dividend (Yield) | 1.85 (4.30%) |
| Volume | 810,300 |
| Average Daily Volume | 1,714,000 |
GSK
VS S&P 500 (SPY)
How do you think GSK will perform vs the S&P 500?
Caps
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
GSK Advanced Details
- CAPS Community Analysis: Commentary, Scorecard
- Advanced Financial Analysis: Historical Prices, Chart, Stats, Ratios, Earnings/Growth Rates, Statements, SEC Filings
GSK News and Commentary
- Biotech Bargains for Your Portfolio – The Motley Fool
- 7 of the Most Efficient Companies on the Planet – The Motley Fool
- 3 China Profit Plays – The Motley Fool
- UPDATE: Ranbaxy Launches Generic Valtrex In US, Shares Rise – SmartMoney
- Vectura First-half Loss Narrows As Novartis Readies Trial – SmartMoney
- Hot Drug Stock in Need of a Chill – SmartMoney
- Ranbaxy: Launched Generic Version Of Valtrex In US On Nov 25 – SmartMoney
- A Schizophrenic Move by Merck? – The Motley Fool
- GlaxoSmithKline Withdraws Avodart US New Drug Application – SmartMoney
- GlaxoSmithKline:Strong Response For Pandemrix In Children 3-17 – SmartMoney
- CDC: Sees Slight Decline In H1N1 Influenza Illnesses – SmartMoney
- WHO: Mutated H1N1 Virus In Norway Sensitive To Antiviral Drugs – SmartMoney
- 4-Star Stocks Poised to Pop: Merck – The Motley Fool
- EU Panel: Affirm Benefits Of Celvapan, Focetria, Pandemrix – SmartMoney
- Pfizer Dodges a Bullet – The Motley Fool
- Why You Can't Afford to Miss These Stocks – The Motley Fool
- Swiss Health Body Expands Use Of Swine-Flu Vaccine Pandemrix – SmartMoney
- UPDATE: FDA Panel Votes Against Approving Xolair In Children – SmartMoney
- The Government Won't Be There for You – The Motley Fool
- VIVUS Gets a Spark – The Motley Fool
RSS Headlines
Fool UK
